1. Show article details.

    BioLife Solutions to Report First Quarter 2021 Financial Results and Provide Business Update on May 13, 2021

    PR Newswire – 4:05 PM ET 05/06/2021

    BOTHELL, Wash. About BioLife Solutions (BLFS) BioLife Solutions (BLFS) is a leading supplier of class-defining cell and gene therapy bioproduction tools and services. Media & Investor RelationsRoderick de GreefChief Financial Officer 686-6002rdegreef@biolifesolutions.com.

  2. Show article details.

    BioLife Solutions Announces Closing of Stirling Ultracold Acquisition and Expanded Partnership with Leading Global Biopharma CDMO

    PR Newswire – 4:05 PM ET 05/03/2021

    BOTHELL, Wash. $35 million to $37 million, with total 2021 revenue of $101 million to $110 million. BioLife also announced that Stirling has expanded its existing partnership with a leading global contract development and manufacturing organization and has been selected by this customer as their preferred provider of ULT storage across their multiple business units.

  3. Show article details.

    BioLife Solutions Launches New High Capacity Controlled Rate Freezer Line with First Shipment to a Leading Cell Therapy Developer

    PR Newswire – 8:00 AM ET 04/15/2021

    BOTHELL, Wash. Todd Berard, BioLife's Chief Marketing Officer, commented, "This product launch expands our Cryogenic Freezer Platform with high capacity controlled rate freezers designed specifically to meet the needs of cell and gene therapy developers.

  4. Show article details.

    BioLife Solutions Appoints Two New Independent Board Directors

    PR Newswire – 8:00 AM ET 04/06/2021

    BOTHELL, Wash. Mike Rice, BioLife CEO, commented, "We are very pleased to welcome Amy and Rachel as new independent directors to BioLife's board. DuRoss will serve on the Audit and Compensation committees and Ellingson will serve on the Compensation and Nominating and Governance committees.

  5. Show article details.

    BRIEF-Stirling Ultracold To Merge Into BioLife Solutions

    Reuters – 5:19 PM ET 03/22/2021

    Stirling Ultracold: * STIRLING ULTRACOLD - SIGNED AGREEMENT TO MERGE INTO BIOLIFE SOLUTIONS. * STIRLING ULTRACOLD - DEAL TO COMBINE EXPERTISE AND EXPAND INDIVIDUAL PRODUCT OFFERINGS FOR BIOPHARMA RESEARCH AND LIFE SCIENCE CUSTOMERS Source text for Eikon: Further company coverage:

  6. Show article details.

    BRIEF-Biolife Solutions To Acquire Stirling Ultracold In An All-Stock Merger

    Reuters – 5:18 PM ET 03/22/2021

    BioLife Solutions Inc (BLFS): * BIOLIFE SOLUTIONS TO ACQUIRE STIRLING ULTRACOLD IN AN ALL-STOCK MERGER. * BioLife Solutions Inc (BLFS) - WILL ISSUE 6.6 MILLION SHARES OF COMMON STOCK FOR 100% OF OUTSTANDING SHARES OF STIRLING IN AN ALL-STOCK TRANSACTION. * BioLife Solutions Inc (BLFS) - SIGNING OF A DEFINITIVE MERGER AGREEMENT TO ACQUIRE GLOBAL COOLING, INC., OPERATING AS STIRLING ULTRACOLD.

  7. Show article details.

    Stirling Ultracold to Merge with BioLife Solutions, the Leader in Gene and Cell Therapy Bioproduction Tools and Services

    PR Newswire – 5:00 PM ET 03/22/2021

    COLUMBUS, Ohio, March 22, 2021 Stirling Ultracold, an Ohio-based manufacturer and provider of the most energy efficient, sustainable ultra-low temperature biorepositories has entered into a definitive agreement to merge with BioLife Solutions (BLFS), a leading provider of bioproduction products and services for the Gene and Cell Therapy markets.

  8. Show article details.

    BRIEF-BioLife Solutions Reports Q4 Adjusted Non-GAAP Loss Per Share $0.01

    Reuters – 4:37 PM ET 03/22/2021

    BioLife Solutions Inc (BLFS): * BIOLIFE SOLUTIONS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2020 FINANCIAL RESULTS. * Q4 ADJUSTED NON-GAAP LOSS PER SHARE $0.01. * Q4 GAAP LOSS PER SHARE $0.06. * Q4 REVENUE ROSE 78 PERCENT TO $14.7 MILLION. * SEES FY 2021 REVENUE UP 110 TO 129 PERCENT. * INTRODUCES GUIDANCE FOR 2021 TOTAL REVENUE OF $101 MILLION TO $110 MILLION.

  9. Show article details.

    BioLife Solutions Announces Fourth Quarter and Full Year 2020 Financial Results

    PR Newswire – 4:05 PM ET 03/22/2021

    BOTHELL, Wash. Mike Rice, BioLife President & CEO, commented, "Despite the COVID-19 pandemic, the BioLife team delivered another quarter and year of stellar operational and financial results.

  10. Show article details.

    Stirling Ultracold Announces Merger Agreement with BioLife Solutions to Further Support Life-Science Industry with Expertise in Ultra-Low Temperature Storage

    PR Newswire – 4:05 PM ET 03/22/2021

    ATHENS, Ohio, March 22, 2021  Stirling Ultracold, a privately-held innovative developer and manufacturer of ultra-low temperature freezers, today announced it has signed a definitive agreement to merge into BioLife Solutions  to combine expertise and expand individual product offerings for biopharma research and life science customers.

  11. Show article details.

    BioLife Solutions to Acquire Stirling Ultracold in an All-Stock Merger

    PR Newswire – 4:03 PM ET 03/22/2021

    BOTHELL, Wash. $48.1 million, a 76% increase over 2019, driven by a 32% increase in biopreservation media revenue, combined with the impact of the results of the Company's prior acquisitions.

  12. Show article details.

    BioLife Solutions to Report Fourth Quarter and Full Year 2020 Financial Results and Provide Business Update on March 22, 2021

    PR Newswire – 8:00 AM ET 03/10/2021

    BOTHELL, Wash. About BioLife Solutions (BLFS) BioLife Solutions (BLFS) is a leading supplier of cell and gene therapy bioproduction products and services. Media & Investor Relations Roderick de Greef Chief Financial and Chief Operating Officer 686-6002 rdegreef@biolifesolutions.com.

  13. Show article details.

    BioLife Solutions Promotes Marcus Schulz to Chief Revenue Officer

    PR Newswire – 8:00 AM ET 02/16/2021

    BOTHELL, Wash. Mike Rice, BioLife Solutions CEO, remarked, "Marcus has demonstrated stellar leadership of our sales team and indirect distribution channel to deliver outstanding results. About BioLife Solutions (BLFS) BioLife Solutions (BLFS) is a leading supplier of class-defining cell and gene therapy bioproduction tools and services.

  14. Show article details.

    iVexSol Announces Series A Funding

    GlobeNewswire – 8:00 AM ET 12/01/2020

    iVexSol, a rapidly growing lentiviral vector manufacturing company, today announced the closure of a $13.0M Series A funding round. iVexSol, Inc. was founded on a next generation manufacturing technology that revolutionizes the production of LVVs; gene delivery vehicles that are a critical raw material in the manufacturing of life-changing cell and gene therapies. iVexSol’s LVV technology is de...

Page:

Today's and Upcoming Events

  • May
    12

    BLFS to announce Q1 earnings (Unconfirmed)

Past Events (last 90 days)

  • Mar
    22

    BLFS announced Q4 earnings.

Data provided by Thomson Reuters © 2021

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.